Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology

Choosing the Right Treatment and Avoiding Harm

At a Glance

Juvenile myoclonic epilepsy is usually treated with broad-spectrum antiseizure medicines that cover multiple seizure types. Valproate can be highly effective but has important risks for pregnancy, while some medicines used for focal epilepsy may worsen JME seizures.

The goal of treating Juvenile Myoclonic Epilepsy (JME) is complete seizure freedom with minimal side effects [1]. Because JME is a generalized epilepsy involving networks throughout the entire brain, the choice of medication—known as an antiseizure medication (ASM)—is critical [2]. Choosing the wrong drug can not only fail to stop seizures but can actively make them worse [3].

The Strategy: Broad-Spectrum Medications

Doctors treat JME using broad-spectrum ASMs. These are medications designed to manage a wide variety of seizure types across the entire brain [4].

  • Valproate (Depakote): Historically, this has been the most effective drug for JME, providing excellent control over myoclonic jerks and convulsions [5][6]. However, it carries significant risks for people of childbearing potential, including serious risks to a developing fetus [7], as well as clinically important dose-related side effects like weight gain, tremor, and liver or pancreatic issues. For this reason, it is often reserved for when other drugs fail in this population [4].
  • Levetiracetam (Keppra): Often used as a first-choice alternative to valproate, it is highly effective for many [5]. A key side effect to watch for is severe mood changes, which can include intense irritability, severe depression, aggression, or suicidal thoughts rather than just colloquial “Keppra-rage” [8][9]. If you experience severe mood symptoms, seek urgent medical advice.
  • Lamotrigine (Lamictal): While it is very effective for generalized convulsions, it is less reliable for myoclonic jerks [10]. In some patients, it can cause a paradoxical reaction, where it actually increases the frequency of the morning jerks [11]. Important Safety Note: Lamotrigine must be started slowly to reduce the risk of a rare but serious skin rash. Seek urgent medical advice if a new rash appears.

Warning: Medications That Require Specialist Review

Certain medications used for “focal” epilepsy (seizures starting in one spot) may worsen particular seizure types and require specialist review for people with JME. These are often narrow-spectrum sodium channel blockers [3]. These drugs can trigger myoclonic status—a state of continuous, severe jerking—or increase the risk of major convulsions [12].

WARNING: Never start, stop, or switch your medication abruptly on your own. If you are currently taking one of these medications, continue taking it exactly as prescribed and contact your neurologist promptly for a review:

  • Carbamazepine (Tegretol) [3]
  • Oxcarbazepine (Trileptal) [12]
  • Phenytoin (Dilantin) [13]
  • Lacosamide (Vimpat) [14]

Understanding “Pseudo-Resistance”

If your seizures are not controlled, it doesn’t always mean the medication is “failing.” True drug-resistant epilepsy is defined as the failure of two appropriate, adequately dosed and tolerated medication regimens. In JME, many cases that seem difficult to treat are actually due to pseudo-resistance [15]. This means the seizures are happening because of external factors rather than the medication itself being ineffective.

Common causes of pseudo-resistance include:

  • Missed Doses: JME is very sensitive to even a single missed dose of medication [16].
  • The Wrong Drug: As mentioned above, being prescribed a “narrow-spectrum” drug by mistake [3].
  • Lifestyle Triggers: Chronic sleep deprivation or alcohol use “overwhelming” the medication’s ability to protect the brain [1][17].
  • Drug Interactions: Certain birth control pills containing estrogen can lower the levels of Lamictal in your blood by more than 50%, making it less effective [13].

If you are taking your medication exactly as prescribed, avoiding triggers, and ruling out interactions but still having seizures, your doctor may then consider you “drug-resistant” and look at adding a second medication or exploring clinical trials [18][19].

Common questions in this guide

What medications are commonly used for juvenile myoclonic epilepsy?
JME is generally treated with broad-spectrum antiseizure medicines because they can cover several seizure types. Valproate is often highly effective but has important risks for people who could become pregnant. Levetiracetam is a common alternative, while lamotrigine may be less reliable for myoclonic jerks and can worsen them in some people.
Which medicines can make JME seizures worse?
Carbamazepine, oxcarbazepine, phenytoin, and lacosamide are medicines used for some focal epilepsies that may worsen myoclonic jerks or increase major convulsions in JME. They can also trigger myoclonic status, meaning prolonged or continuous severe jerking. Do not stop one suddenly; continue taking it as prescribed and contact your neurologist promptly for review.
What should I do if levetiracetam causes mood changes?
Levetiracetam can cause severe irritability, depression, aggression, or suicidal thoughts in some people. Severe mood symptoms require urgent medical advice. Do not change the dose or switch medicines on your own; contact your neurologist to plan the safest next steps.
Can lamotrigine make morning jerks worse?
Yes. Although lamotrigine can help generalized convulsions, it is less reliable for myoclonic jerks and can increase morning jerks in some people. It should be started slowly, and a new rash requires urgent medical advice.
Why am I still having seizures despite taking medication?
Poor seizure control does not always mean the medicine has failed. Missed doses, sleep deprivation, alcohol, an unsuitable narrow-spectrum drug, or an interaction—such as estrogen-containing birth control lowering lamotrigine levels—can cause pseudo-resistance. If these issues are addressed and seizures continue, your doctor may evaluate for drug-resistant epilepsy and discuss a second medicine or clinical trials.
Can I stop or switch my JME medication by myself?
No. Abruptly stopping or switching an antiseizure medication can increase seizure risk. Continue taking it exactly as prescribed and contact your neurologist for guidance about any medication change.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my current medication considered 'broad-spectrum,' and does it specifically treat all three seizure types in my history?
  2. 2.Was my previous medication a 'narrow-spectrum' sodium channel blocker, and could that have contributed to my recent seizure frequency?
  3. 3.Since I've noticed an increase in morning jerks since starting Lamictal (lamotrigine), could this be a 'paradoxical' reaction?
  4. 4.If I'm struggling with mood changes or irritability on Keppra (levetiracetam), what are the safest next steps for switching medications?
  5. 5.Can we review my 'Seizure Action Plan' to ensure I know how to handle breakthrough seizures safely?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Status epilepticus in patients with juvenile myoclonic epilepsy: Frequency, precipitating factors and outcome.

    Oğuz-Akarsu E, Aydin-Özemir Z, Bebek N, et al.

    Epilepsy & behavior : E&B 2016; (64(Pt A)):127-132 doi:10.1016/j.yebeh.2016.07.038.

    PMID: 27736659
  2. 2

    ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.

    Hirsch E, French J, Scheffer IE, et al.

    Epilepsia 2022; (63(6)):1475-1499 doi:10.1111/epi.17236.

    PMID: 35503716
  3. 3

    Reconsidering the role of selective sodium channel blockers in genetic generalized epilepsy.

    Cerulli Irelli E, Morano A, Fanella M, et al.

    Acta neurologica Scandinavica 2021; (144(6)):647-654 doi:10.1111/ane.13509.

    PMID: 34314016
  4. 4

    Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE).

    Mostacci B, Ranzato F, Giuliano L, et al.

    Seizure 2021; (85()):26-38 doi:10.1016/j.seizure.2020.12.005.

    PMID: 33418162
  5. 5

    Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy: A systematic review and meta-analysis.

    Pereira ARO, Leão IA, Dias LA, Moura RF

    Epilepsy & behavior : E&B 2025; (171()):110512 doi:10.1016/j.yebeh.2025.110512.

    PMID: 40450767
  6. 6

    Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients.

    Zhang Y, Chen J, Ren J, et al.

    Epilepsia open 2019; (4(2)):302-308 doi:10.1002/epi4.12321.

    PMID: 31168497
  7. 7

    Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

    Stephen LJ, Brodie MJ

    CNS drugs 2020; (34(2)):147-161 doi:10.1007/s40263-020-00698-5.

    PMID: 31983023
  8. 8

    Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.

    Tabrizi N, Zarvani A, Rezaei P, et al.

    Epilepsy research 2019; (157()):106214 doi:10.1016/j.eplepsyres.2019.106214.

    PMID: 31627041
  9. 9

    Long-term outcomes of treatment with levetiracetam and valproate in idiopathic generalized epilepsy.

    Tabrizi N, Cheraghmakani H, Samadi F, Alizadeh-Navaei R

    Seizure 2025; (127()):66-70 doi:10.1016/j.seizure.2025.03.004.

    PMID: 40117784
  10. 10

    Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.

    Milano C, Turco F, Pizzanelli C, et al.

    Epilepsy & behavior : E&B 2021; (115()):107706 doi:10.1016/j.yebeh.2020.107706.

    PMID: 33423017
  11. 11

    Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy.

    Gesche J, Hjalgrim H, Rubboli G, Beier CP

    Epilepsy research 2021; (170()):106547 doi:10.1016/j.eplepsyres.2020.106547.

    PMID: 33421702
  12. 12

    Juvenile Myoclonic Epilepsy: Myoclonic Status Epilepticus without Coma - Report of Three Cases.

    Murthy JMK

    Journal of epilepsy research 2020; (10(2)):92-95 doi:10.14581/jer.20015.

    PMID: 33659202
  13. 13

    Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

    Serafini A, Gerard E, Genton P, et al.

    CNS drugs 2019; (33(3)):195-208 doi:10.1007/s40263-018-00602-2.

    PMID: 30747367
  14. 14

    Unmasking of myoclonus by lacosamide in generalized epilepsy.

    Birnbaum D, Koubeissi M

    Epilepsy & behavior case reports 2017; (7()):28-30 doi:10.1016/j.ebcr.2016.09.006.

    PMID: 28239547
  15. 15

    Juvenile Myoclonic Epilepsy in Rural Western India: Not Yet a Benign Syndrome.

    Desai D, Desai S, Jani T

    Epilepsy research and treatment 2016; (2016()):1435150 doi:10.1155/2016/1435150.

    PMID: 27818795
  16. 16

    Impact of sleep disorders on the risk of seizure recurrence in juvenile myoclonic epilepsy.

    Buratti L, Natanti A, Viticchi G, et al.

    Epilepsy & behavior : E&B 2018; (80()):21-24 doi:10.1016/j.yebeh.2017.11.023.

    PMID: 29396358
  17. 17

    Analysis of Clinical Characteristics, Background, and Paroxysmal Activity in EEG of Patients with Juvenile Myoclonic Epilepsy.

    Santiago-Rodríguez E, Zaldívar-Uribe E

    Brain sciences 2021; (12(1)) doi:10.3390/brainsci12010029.

    PMID: 35053773
  18. 18

    Prognostic factors in patients with refractory idiopathic generalized epilepsy.

    Gomez-Ibañez A, McLachlan RS, Mirsattari SM, et al.

    Epilepsy research 2017; (130()):69-73 doi:10.1016/j.eplepsyres.2017.01.011.

    PMID: 28157601
  19. 19

    Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy.

    Ascoli M, Mastroianni G, Gasparini S, et al.

    Expert review of neurotherapeutics 2021; (21(11)):1265-1273 doi:10.1080/14737175.2021.1931126.

    PMID: 33993822

This page is for informational purposes only and does not constitute medical advice. Do not start, stop, or switch an antiseizure medication without speaking with your neurologist.

Get notified when new evidence is published on Juvenile myoclonic epilepsy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.